#USA #Clinical AI #Boxborough #Janus Data #Q2BI

The Independent Launch of Janus Data Intelligence

On March 24, 2026, Q-Square Business Intelligence, Corp. (commonly referred to as Q2BI), celebrated a significant milestone with the independent launch of Janus Data Intelligence, Corp. (JDIX). This new company emerges from Q2BI and specializes in clinical AI technologies. JDIX aims to enhance clinical development through advanced data intelligence solutions.

The JDIQ™ and JDIM™ Platforms

JDIX has unveiled two flagship platforms—JDIQ™ and JDIM™—which are designed to improve data quality, facilitate real-time monitoring, and enable smarter decision-making for clinical development projects. These cutting-edge tools have already been utilized across several biopharma clinical programs during JDIX's incubation at Q2BI. Both platforms have been rigorously validated in real-world scenarios, garnering positive feedback from numerous biopharma clients and showcasing their effectiveness in enhancing data quality and optimizing clinical review cycles.

Foundation of Expertise

Since its establishment in 2009, Q2BI has successfully completed over 1,800 clinical trial projects, contributing to more than 50 successful New Drug Applications (NDAs) and Biologics License Applications (BLAs) worldwide. This rich history reflects the company’s deep expertise in biometrics and clinical data, laying a solid foundation for JDIX's future innovations.

Investment in AI and Data Science

Recognizing the vital role of artificial intelligence in clinical research, Q2BI made substantial investments in this area beginning in 2021. The establishment of a dedicated Data Science Department enabled the company to foster AI research and development capabilities. These efforts have resulted in several patents related to AI and the creation of specialized AI tools specifically catered for clinical research.

Gary Huang, the Founder and CEO of Q2BI, noted, “JDIX is a testament to our commitment to integrating AI into the daily practices of clinical teams—transforming it from a mere concept into a reliable resource.” He emphasized the importance of seeing their technologies actively utilized within clinical programs to help organizations accelerate their processes and ask more probing questions to enhance decision-making confidence.

Dual Tracks of Innovation

At present, Q2BI’s statisticians and data scientists are focused on two complementary innovation tracks. They leverage AI technologies to redefine clinical development for biopharmaceutical firms while also utilizing their extensive biometric knowledge to assist AI companies in refining model accuracy and reliability. This strategic evolution has allowed Q2BI to expand its role from solely a biometrics contract research organization (CRO) to a comprehensive clinical data intelligence company, serving both the life sciences and AI sectors.

As the industry gradually embraces AI methodologies, Q2BI anticipates a surge of new opportunities to enhance and expedite global drug development in the coming decade. The company is dedicated to advancing clinical data intelligence, supporting both pharmaceutical innovators and AI technology leaders in their pursuits.

About Q2BI

Q2BI specializes in clinical data intelligence, focusing on biometrics, data science, and AI-enabled clinical solutions. Featuring extensive expertise in clinical statistics, data management, pharmacokinetics (PK), and regulatory submissions, the company collaborates with both biopharma and AI organizations to facilitate the advancement of innovative medicinal products.

For more information, visit www.q2bi.com.